NVCT Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. (NVCT) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.6% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Nuvectis Pharma, Inc.
Nuvectis Pharma Inc. is a biopharmaceutical company. It focused on the development of innovative precision medicines for serious conditions of unmet medical need in oncology. Nuvectis Pharma Inc. is based in Fort Lee, NJ.
Sector
Healthcare
Industry
Biotechnology